Biopharma Firms Rush to Sci-Tech Innovation Board in H1 2026 with Record IPO Filings

　　【PharmNet Corporate News] Since 2026, domestic biopharmaceutical companies have witnessed a surge in concentrated IPO filings on the STAR Market. It is reported that by the end of June, the STAR Market had accepted listing applications from 16 biopharmaceutical companies this year. The peak occurred on June 29 and 30.
 

On June 30, Tsingke Biotech’s initial public offering (IPO) on the STAR Market was accepted for review. Reportedly, the company specializes in the field of synthetic biology, with its core business leveraging independently developed key reagents, vectors, and synthesis equipment. By deeply integrating “AI + molecular intelligent manufacturing” technologies, it provides high-efficiency, high-quality gene synthesis and gene sequencing services, along with related products, to support basic scientific research, frontier technological studies, and industrial applications.
 

For this IPO, the company plans to raise RMB 1 billion. Of this amount, RMB 550 million will be allocated to Tsingke Biotech’s biological manufacturing facility project, RMB 200 million to the construction of a gene synthesis and application technology R&D center, RMB 150 million to marketing network and informatization projects, and RMB 100 million to supplement working capital.
 

On June 30, Beyotime’s IPO application on the STAR Market was accepted. For this listing attempt, Beyotime plans to raise RMB 800 million to fund the construction of production facilities, R&D centers, and a digital warehousing system.
 

According to available information, Beyotime is an integrated enterprise specializing in the research and development, production, and sales of products for scientific research.Biological Reagents, a kit manufacturer that also provides supporting laboratory consumables and instruments, along with related technical services. From 2023 to 2025, the company’s revenue increased from RMB 291 million to RMB 371 million, while its net profit rose from RMB 132 million to RMB 174 million.
 

H&H Healthcare’s STAR Market IPO was accepted by the Shanghai Stock Exchange on June 30. The company is primarily engaged in the research and development, manufacturing, and sales of innovative medical devices in the field of pan-vascular intervention. During the reporting period, the company remained unprofitable, with net profits attributable to shareholders amounting to RMB -201 million, RMB -190 million, and RMB -219 million for 2023, 2024, and 2025, respectively, resulting in cumulative losses exceeding RMB 600 million.
 

The company plans to raise RMB 1.11 billion, which will be allocated to the construction of a new production center (RMB 430 million), new product development (RMB 210 million), overseas clinical trials and regulatory registrations (RMB 220 million), and replenishment of working capital (RMB 250 million). Among these, the new project will expand the production capacity of structural heart intervention products, covering K-Clip and its upgraded version K-Plus, as well as Tri-Cap, L-Clip, D-Clip, and other products.
 

Geneseeq’s IPO on the STAR Market was also accepted on June 29. Reportedly, it is a technology-driven company dedicated to the clinical translation and application of high-throughput gene sequencing technologies, providing molecular diagnostic services and products for precision oncology. This IPO marks the company’s second attempt to list on the STAR Market.
 

The prospectus indicates that Geneseeq plans to raise RMB 1.7 billion in this IPO, with the proceeds intended for the research and development of the “Jinling Cohort” and pan-cancer early screening kits, the R&D of multi-cancer early screening kits for gastrointestinal cancers, the R&D of minimal residual disease (MRD) monitoring kits, and the research on the application of large AI language models in precision medicine throughout the entire cancer care continuum, among other projects.
 

　　……
 

Notably, a surge in filings does not imply lenient review; regulatory scrutiny of “genuine innovation” is being continuously strengthened. The quality of clinical data for core pipelines, commercialization potential, and cash flow management capabilities remain critical determinants of whether pharmaceutical companies can successfully achieve listing.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice for any person.